Blepharospasm Treatment Market Size & Share, by Type (Injections, Oral Medications), End User (Hospitals, Clinics, Specialty Neurology Centers) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5484
  • Published Date: Jan 03, 2024
  • Report Format: PDF, PPT

Companies Dominating the Blepharospasm Treatment Market

    • Allergan plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Ipsen Pharma
    • Medytox Inc.
    • Revance Therapeutics, Inc.
    • Merz Pharma GmbH & Co. KGaA
    • US WorldMeds, LLC
    • Evolus, Inc.
    • Lanzhou Institute of Biological Products Co., Ltd.
    • Hugel Inc.
    • AbobotulinumtoxinA, Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • Ipsen acquired Epizyme, Inc., a US-based biotech company developing novel EZH2 inhibitors for cancer treatment, for USD 1.45 billion. This acquisition expanded Ipsen's oncology portfolio and added Tazverik® (tazemetostat), a first-in-class treatment for epithelioid sarcoma, to their pipeline.
  • Ipsen completed the acquisition of Albireo Pharma, Inc., a US-based leader in bile-acid modulators for rare liver diseases, for USD 42.00 per share plus a contingent value right. This acquisition strengthened Ipsen's rare disease portfolio with promising treatment for pediatric and adult cholestatic liver diseases and innovative pipeline potential.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5484
  • Published Date: Jan 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of blepharospasm treatment is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market Allergan plc, Ipsen Pharma, Medytox Inc., Revance Therapeutics, Inc., Merz Pharma GmbH & Co. KGaA, US WorldMeds, LLC, and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying